대한두경부종양학회지 (Korean Journal of Head & Neck Oncology)

  • 제35권2호
  • /
  • Pages.11-17
  • /
  • 2019
  • /
  • 1229-5183(pISSN)
  • /
  • 2586-2553(eISSN)
대한두경부종양학회 (The Korean Society for Head and Neck Oncology)
권호 표지
DOI QR코드

DOI QR Code

갑상선 유두암의 일차 수술 후 경부 림프절 재발의 원인

The Cause of Cervical Lymph Node Recurrence after the Initial Surgery of Papillary Thyroid Carcinoma

  • 김형규 (아주대학교 의과대학 외과학교실) ;
  • 하은주 (아주대학교 의과대학 영상의학과학교실) ;
  • 이인화 (아주대학교 의과대학 외과학교실) ;
  • 이정훈 (아주대학교 의과대학 외과학교실) ;
  • 소의영 (아주대학교 의과대학 외과학교실)
  • Kim, Hyeung Kyoo (Department of Surgery, Ajou University School of Medicine) ;
  • Ha, Eun Ju (Department of Radiology, Ajou University School of Medicine) ;
  • Lee, Inhwa (Department of Surgery, Ajou University School of Medicine) ;
  • Lee, Jeonghun (Department of Surgery, Ajou University School of Medicine) ;
  • Soh, Euy Young (Department of Surgery, Ajou University School of Medicine)
  • 투고 : 2019.10.26
  • 심사 : 2019.11.18
  • 발행 : 2019.11.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background/Objectives: Papillary thyroid carcinoma (PTC) has generally an indolent character with a good prognosis. However, recurrence remains a major concern for the patients during their lifetime. Despite the slowly progressing character of PTC, recurrence can occur within a short period after initial surgery. This study aimed to determine the clinical findings and cause of recurrence in patients who underwent re-operative surgery due to neck node recurrence by reviewing the CT (computed tomographic) scan imaging of the recurrence of PTC retrospectively. Materials & Methods: We reviewed the medical records of patients referred to Ajou University Hospital from January 2002 to January 2018. All patients had re-operative surgery due to neck node recurrence and CT scan results of preoperative evaluation and postoperative follow up. Over this period, 110 patients who underwent re-operation due to neck node recurrence with a CT scan were included in our cohort, resulting in a total of 220 re-operations. Results: The time from initial operation to first re-operation was examined in 110 patients. The median time to re-operation was 28 months, with a range of 4 months to 186 months. Most re-operations (82.7%) occurred within the first five years, 43.6% were in the first two years from the initial surgery. The result of the retrospective CT review showed newly developed cases (21,19.1%), missed diagnosis cases (42,38.2%), real recur cases after surgery (33,30.0%), and remnant lymph nodes (LNs) cases (14,12.7%). We further sub-analyzed 14 cases with remnant LNs. Reasons for remnant LNs included insufficient operation (N=5) and beyond general surgical extent. (N=9). Conclusion: Re-operation due to cervical lymph node recurrence is mostly a persistent disease. They included a missed diagnosis and incomplete operation. These finding may reduce the reoperation of cervical lymph node recurrence by accurate preoperative evaluation and complete surgical resection at the initial surgery.

키워드

참고문헌

  1. Ito Y, Miyauchi A. Nonoperative management of low-risk differentiated thyroid carcinoma. Curr Opin Oncol. 2015;27:15-20. https://doi.org/10.1097/CCO.0000000000000143
  2. Ahn HS, Kim HJ, Welch HG. Korea's thyroid-cancer "epidemic"--screening and overdiagnosis. N Engl J Med. 2014;371:1765-1767. https://doi.org/10.1056/NEJMp1409841
  3. Ahn JE, Lee JH, Yi JS, Shong YK, Hong SJ, Lee DH, et al. Diagnostic accuracy of CT and ultrasonography for evaluating metastatic cervical lymph nodes in patients with thyroid cancer. World J Surg. 2008;32:1552-1558. https://doi.org/10.1007/s00268-008-9588-7
  4. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297-306. https://doi.org/10.1056/NEJM199801293380506
  5. Bates MF, Lamas MR, Randle RW, Long KL, Pitt SC, Schneider DF, et al. Back so soon? Is early recurrence of papillary thyroid cancer really just persistent disease? Surgery. 2018;163:118-123. https://doi.org/10.1016/j.surg.2017.05.028
  6. Lee HS, Roh JL, Gong G, Cho KJ, Choi SH, Nam SY, et al. Risk factors for re-recurrence after first reoperative surgery for locoregional recurrent/persistent papillary thyroid carcinoma. World J Surg. 2015;39:1943-1950. https://doi.org/10.1007/s00268-015-3052-2
  7. Haugen BR, Sawka AM, Alexander EK, Bible KC, Caturegli P, Doherty GM, et al. American thyroid association guidelines on the management of thyroid nodules and differentiated thyroid cancer task force review and recommendation on the proposed renaming of encapsulated follicular variant papillary thyroid carcinoma without invasion to noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Thyroid. 2017;27:481-483. https://doi.org/10.1089/thy.2016.0628
  8. Ruter A, Smeds S, Lennquist S. Value of serum thyroglobulin measurement in patients operating on for well differentiated thyroid carcinoma. Eur J Surg. 1998;164:665-671. https://doi.org/10.1080/110241598750005543
  9. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418-428. https://doi.org/10.1016/0002-9343(94)90321-2
  10. Kim SJ, Park SY, Lee YJ, Lee EK, Kim SK, Kim TH, et al. Risk factors for recurrence after therapeutic lateral neck dissection for primary papillary thyroid cancer. Ann Surg Oncol. 2014;21:1884-1890. https://doi.org/10.1245/s10434-014-3507-y
  11. Lee CW, Roh JL, Gong G, Cho KJ, Choi SH, Nam SY, et al. Risk factors for recurrence of papillary thyroid carcinoma with clinically node-positive lateral neck. Ann Surg Oncol. 2015;22:117-124. https://doi.org/10.1245/s10434-014-3900-6
  12. Randolph GW, Duh QY, Heller KS, LiVolsi VA, Mandel SJ, Steward DL, et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid. 2012;22:1144-1152. https://doi.org/10.1089/thy.2012.0043
  13. Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014;140:317-322. https://doi.org/10.1001/jamaoto.2014.1
  14. Randle RW, Bushman NM, Orne J, Balentine CJ, Wendt E, Saucke M, et al. Papillary thyroid cancer: The good and bad of the "Good Cancer". Thyroid. 2017;27:902-907. https://doi.org/10.1089/thy.2016.0632
  15. Durante C, Montesano T, Torlontano M, Attard M, Monzani F, Tumino S, et al. Papillary thyroid cancer: Time course of recurrences during postsurgery surveillance. J Clin Endocrinol Metab. 2013;98:636-642. https://doi.org/10.1210/jc.2012-3401
  16. Grogan RH, Kaplan SP, Cao H, Weiss RE, Degroot LJ, Simon CA, et al. A study of recurrence and death from papillary thyroid cancer with 27 years of median follow-up. Surgery. 2013;154:1436-1446;discussion 1446-1437. https://doi.org/10.1016/j.surg.2013.07.008
  17. Liu FH, Kuo SF, Hsue h C, Chao TC, Lin JD. Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis. J Surg Oncol. 2015;112:149-154. https://doi.org/10.1002/jso.23967
  18. Ahn D, Sohn JH, Kim H. Surgeon-performed intraoperative tumor localization in recurrent papillary thyroid carcinoma by ultrasound-guided intratumoral indigo carmine injection. World J Surg. 2014;38:1995-2001. https://doi.org/10.1007/s00268-014-2504-4
  19. Harari A, Sippel RS, Goldstein R, Aziz S, Shen W, Gosnell J, et al. Successful localization of recurrent thyroid cancer in reoperative neck surgery using ultrasound-guided methylene blue dye injection. J Am Coll Surg. 2012;215:555-561. https://doi.org/10.1016/j.jamcollsurg.2012.06.006
  20. Sippel RS, Elaraj DM, Poder L, Duh QY, Kebebew E, Clark OH. Localization of recurrent thyroid cancer using intraoperative ultrasound-guided dye injection. World J Surg. 2009;33:434-439. https://doi.org/10.1007/s00268-008-9797-0
  21. Hayward NJ, Grodski S, Yeung M, Johnson WR, Serpell J. Recurrent laryngeal nerve injury in thyroid surgery: A review. ANZ J Surg. 2013;83:15-21. https://doi.org/10.1111/j.1445-2197.2012.06247.x
  22. Ryu YJ, Cho JS, Park MH, Yoon JH. Identifying risk factors of recurrence for clinically node negative papillary thyroid carcinoma with pathologic N1a. BMC Surg. 2019;19:78. https://doi.org/10.1186/s12893-019-0541-5